By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv
Survodutide and fatty liver: a 58.7% drop in liver fat
The new study on survodutide and fatty liver brings interesting news for people living with obesity. Survodutide is an experimental drug given as a weekly injection. It acts on two receptors: GLP-1 and glucagon. In a phase 3 study published in Nature Medicine, liver fat fell by an average of 58.7% after 48 weeks. In addition, body weight dropped by 12.2%, and markers of liver inflammation improved.
Not just weight loss, but treating the metabolic disease
MASLD is fatty liver disease linked to a metabolic disorder. It is one of the most common consequences of obesity. According to a global meta-analysis, it affects about 75% of people with obesity. Roughly a third of them have the inflammatory form, MASH, or metabolic dysfunction-associated steatohepatitis.
In recent years, our approach to treatment has been changing. In the past, we saw obesity, diabetes, fatty liver, high blood pressure and high blood lipids as unrelated diseases. Today, we understand that they are different faces of the same metabolic disorder. That is why the joint European guidelines on liver disease, diabetes and obesity recommend treating them all together. This is where the new metabolic drugs come into the picture. For a broad overview of diagnosis and treatment, see my guide to diagnosing and reversing fatty liver.
What is survodutide?
Survodutide is a once-weekly injection, and it is still in development. Unlike drugs that act only on GLP-1, it is a dual agonist, meaning it activates two receptors. GLP-1 activity regulates appetite, fullness and blood sugar. Activating the glucagon receptor, on the other hand, affects energy expenditure and fat breakdown, especially in the liver.
The researchers designed the drug to mimic oxyntomodulin. This natural gut hormone activates both receptors. You can read more about the drug and the diabetes studies in my article on survodutide in obesity and type 2 diabetes.
The SYNCHRONIZE-MASLD trial: survodutide and fatty liver
This randomized, double-blind, placebo-controlled trial enrolled 216 adults with obesity and at-risk MASLD. Their average age was 55.8 years. Their average BMI was 39.6, and their average weight was 108.3 kg. In addition, 38.4% of them had type 2 diabetes.
Participants received either survodutide 6 mg once a week or a placebo. Everyone also received diet and exercise counseling. The trial lasted 48 weeks. Most participants did not have cirrhosis or advanced MASH. For most of them, the disease was at a relatively early stage: fat, signs of inflammation and mild to moderate fibrosis. In other words, these are exactly the patients we see in the clinic every day.
84% achieved a meaningful drop in liver fat
One of the trial’s two main goals was a reduction of at least 30% in liver fat. The team measured it with MRI-PDFF, an MRI scan that measures the percentage of fat in the liver. The result is striking: 84.2% of patients on survodutide reached this goal, compared with 24.3% on placebo.
Moreover, the depth of the response is especially impressive. A reduction of at least 50% occurred in 75.3% of patients, compared with only 8.6% on placebo. A reduction of at least 70% occurred in 55.5%, compared with 2.9%. Finally, in 61.0% of patients, liver fat fell below 5%, which is the normal range. In the placebo group, only 5.7% got there.
And what happened to weight?
The trial also met its second goal. Among those who stayed on treatment, weight fell by 12.2%, compared with 1.0% on placebo. In an analysis that also counted treatment discontinuations, the drop was 8.7% versus 1.4%. In addition, 79.1% of patients lost at least 5% of their body weight.
This has an interesting implication. The liver improved substantially even though weight loss was modest compared with some of the new drugs. So the drug’s action on the glucagon receptor may have a direct effect on the liver. However, the study cannot separate a direct drug effect from the effect of weight loss.
Survodutide and fatty liver: inflammation markers improved too
The researchers did not stop at liver fat. The liver enzyme ALT fell by 36.8% with survodutide, compared with 11.0% on placebo. The enzyme AST fell by 27.9% versus 7.2%. Furthermore, among patients who started with high ALT, 82.1% returned to normal values, compared with 27.3% on placebo.
The cT1 score also improved. This MRI measure reflects inflammation and scarring in the liver. These markers are still no substitute for a biopsy showing that fibrosis has regressed. Still, they reinforce the impression that the change is more than just “melting away fat.” You can read about treating the advanced stage in my article on liver fibrosis and MASH.
The heart and metabolism benefited too
The effect went beyond the liver. Waist circumference shrank by 11.1 cm, compared with 1.9 cm on placebo. Systolic blood pressure fell by 7.4 mmHg more than on placebo. In addition, several markers improved: HbA1c (average blood sugar over three months), triglycerides, cholesterol, insulin resistance, uric acid and CRP, a marker of inflammation in the blood.
This may be the study’s biggest message. The new obesity drugs are gradually becoming treatments for the whole metabolic disease, not just tools for “shedding pounds.”
Survodutide and fatty liver: what about side effects?
As expected from a drug with GLP-1 activity, the most common side effects were digestive: nausea, vomiting, diarrhea and constipation. Most appeared while the dose was being increased, and most were mild to moderate. In addition, heart rate rose by an average of 3.6 beats per minute, compared with 0.8 on placebo.
That said, I don’t want to gloss over one point. In the survodutide group, 19.9% of patients stopped treatment because of side effects, compared with 4.3% on placebo. The researchers themselves note that a more flexible dose escalation may improve tolerability. On the other hand, there were no confirmed cases of drug-induced liver injury, acute pancreatitis, pancreatic cancer or thyroid cancer.
What’s new since: the SYNCHRONIZE program moves forward
Over the past few months, more results have come out. In SYNCHRONIZE-1, in people with obesity but without diabetes, weight loss reached up to 16.6% after 76 weeks, compared with 3.2% on placebo. In October 2026, NEJM published the SYNCHRONIZE-2 trial in people with obesity and diabetes. There, weight fell by up to 13.1%, compared with 3.1% on placebo. Meanwhile, the LIVERAGE trial is still underway, testing the drug in MASH with moderate to advanced fibrosis.
Is the survodutide and fatty liver story settled?
Not yet. Survodutide is an investigational drug, and as of October 2026, no country has approved it. Therefore, it is not a routine treatment for MASLD. In the meantime, there are approved drugs with liver data, such as Wegovy for fatty liver.
The study also has several limitations. It lasted only 48 weeks and included 216 patients. Almost all sites were in the United States, with one site in Spain. In addition, most participants did not have a biopsy. As a result, we don’t yet know whether the improvement will translate into less cirrhosis, liver failure, liver cancer and heart disease. Likewise, we should not conclude from this study that the drug treats advanced fibrosis.
A new era in treating obesity and fatty liver
In my view, this study matters more than the question of whether survodutide itself will lead the market. The data on survodutide and fatty liver show where the field is heading. We are moving from treatment that focuses on the number on the scale to treatment that changes the biology of the disease. The goals: less fat in the liver and belly, better insulin sensitivity and less inflammation. More drugs are on the way, including retatrutide, which also affects the liver.
For people with obesity and fatty liver, this is a completely different way of thinking. The goal is not just to be thin. Rather, the goal is to reach old age with a healthy liver, a healthy heart, strong muscles and a normal metabolism. In other words, the main aim is to extend our healthy years.
The information in this article is general and does not replace personalized medical advice.
Questions and answers about survodutide and fatty liver
Is survodutide similar to Wegovy?
Partly. Both drugs act on the GLP-1 receptor. However, survodutide also activates the glucagon receptor.
Is it already available for treating obesity?
No. The drug is still in clinical development and is not approved for use.
Does it “make fatty liver disappear”?
In the study, liver fat fell below 5% in 61.0% of patients after 48 weeks. That is an impressive figure. Even so, it does not necessarily equal a full cure of the liver disease or of fibrosis.
Is the liver improvement due only to weight loss?
Probably not only. The researchers suspect that the action on the glucagon receptor plays a special role in the liver. But the current study does not prove how much each mechanism contributes.
What is the most important lesson from the study?
The next generation of obesity treatment will measure more than kilograms. It will also measure which organs and metabolic diseases improved along the way.
References
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
The studies were funded by Boehringer Ingelheim, the company developing the drug.
